BioSpace News Archive

New senior executives strengthen regulatory and market access capabilities as the Company prepares to transition to a commercial organization

Dr.Felker and Dr. Udelson join current advisors to support the development ofalfapump® DSR for the management of fluid overload in patients with heart failure

The recent novel Coronavirus outbreak in 2019 has led to the use of several types of swabs, media, and kits to test the collected samples for COVID-19.

Increased occurrence of various eye disorders across all worldwide locations is estimated to spur the demand opportunities in the global eye drop dispenser market during the assessment period of 2019 to 2029.

Medical aesthetic devices are those medical devices that are utilized for the purposes of cosmetic procedures, which comprise skin tightening, aesthetic implants, anti-aging, excess fat removal, unwanted hair removal, unwanted hair removal, and plastic surgery.

The global photodynamic therapy market is estimated to show promising sales avenues during the assessment period of 2019 to 2029.

United Therapeutics Corporation announced it will present clinical trial data on Tyvaso® Inhalation Solution in patients with pulmonary hypertension associated with interstitial lung disease at CHEST 2020, the annual meeting of the American College of Chest Physicians, which will be held on October 18-21.

Evelo Biosciences, Inc., a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting biologics, announced that it will host a key opinion leader discussion on the unmet need in psoriasis and atopic dermatitis, including the potential of EDP1815 to serve as a new therapeutic option for patients living with mild to moderate disease.

Ina Phase 1/2interventional study, preliminary open-label safety resultsin first six patientssupport advancementof APL-9, an investigational targeted C3 therapy, for severe COVID-19; additional 60-patient randomized, double-blind, controlled study cohort is currently enrolling

Precision BioSciences, Inc., a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, announced that the U.S. Patent and Trademark Office’s Patent Trial and Appeal Board has ruled in favor of Precision BioSciences in two patent interference proceedings that challenged nine U.S. patents owned by Precision.